Patents
Seraphina Therapeutics has exclusive and global licensing rights from the U.S. Navy and the United States of America for commercialization and use of C15:0, including those described in U.S. Patent No. 11,116,740 C1.
-
US11116740 C1
-
US10449170
-
US10449171
-
US9662306
-
US10022347
-
US10,238,618 B2
-
US10,307,388 B2
-
US18/168,382
-
US18/170,379
-
US17/086,198
-
US18/447,059
-
AU2019271067
-
AU2021329343
-
AU2021329909
-
CA3099561
-
CA3189188
-
CA3039591
-
CA3039594
-
EU3562480
-
EU2159078.4
-
EU21859083.4
-
EU19804528.8
-
EU18870336.7
-
EU21189054.6
-
EU23169882
-
FR3562841
-
DE602018022346
-
IT502021000097403
-
JP7064879
-
JP7037367
-
JP7266366
-
JP2023-512165
-
JP2020-564401
-
JP2023-067618
-
MX378434
-
MX385604
-
MX376781
-
MX2020/011533
-
ES3562841
-
GB3562841
